Search Result for Drug name




Albendazole, a broad-spectrum oral antihelminthic is a benzimidazole carbamate class of drug. Albendazole thought to act against nematodes by inhibiting microtubule synthesis and also has larvicidal action. (1)

It is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. For treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. For adults and children older than 2 years of age with ascariasis and hookworm infections For cutaneous larva migrans, visceral larva migran), intestinal capillariasis, microsporidial infections, and gnathostomiasis (2)

contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds (2)

Abdominal Pain, Nausea/Vomiting, Headache, Dizziness/Vertigo, Reversible Alopecia Hypersensitivity reactions, including rash and urticaria. reversible reductions in total white blood cell count. Granulocytopenia, agranulocytosis, or pancytopenia. Elevations of hepatic enzymes, hepatitis, acute liver failure. (2)

Albendazole does induce cytochrome P450 1A in human hepatoma cells. Therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment (2)

Some people, particularly young children, may experience difficulties swallowing the tablets whole. In young children, the tablets should be crushed or chewed and swallowed with a drink of water Women of childbearing age should be cautioned against becoming pregnant while on albendazole or within 1 month of completing treatment caution should be exercised when albendazole is administered to a nursing woman Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Experience in patients 65 years of age or older is limited. (2)

Available as chewable/plain tablet 150, 200, 400 mg & 1.5g; capsule400 mg; oral suspension 200 mg/5 ml; SyRUP200 mg/5 ml; drops10 ml (200 mg/ml)3 Hydatid Disease: 400 mg twice daily, with meals, 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles. Neurocysticercosis: 400 mg twice daily, with meals, 8-30 days. For ascariasis and hookworm infections, the treatment is a single dose of 400 mg orally (repeated for 2–3 days for heavy ascaris infections and in 2 weeks for pinworm infections). In the treatment of cutaneous larva migrans (400 mg daily for 3 days), visceral larva migrans (400 mg twice daily for 5 days), intestinal capillariasis (400 mg daily for 10 days), microsporidial infections (400 mg twice daily for 2 weeks or longer), and gnathostomiasis (400 mg twice daily for 3 weeks). (2)

1. McCarthy J, Loukas A, Hotez PJ. Chemotherapy of Helminth Infection. In: Brunton L, Chabner B, Knollmann B eds. Goodman & Gilman’s The Pharmacological basis of Therapeutics. 12th ed. China: McGraw Hill; 2011. p1443-61. 2. ALBENZA. [Internet]. [cited 2013 Sept 8]. Available from: 3. National Formulary of India. 4 th ed. Government of India, Ministry of Health and Family Welfare. India: Indian Pharmacopoeia Commission; 2011